Loading...
XNAS
NAGE
Market cap1.05bUSD
Jun 10, Last price  
13.52USD
Name

Chromadex Corp

Chart & Performance

D1W1MN
No data to show
P/E
122.95
P/S
10.55
EPS
0.11
Div Yield, %
Shrs. gr., 5y
6.92%
Rev. gr., 5y
16.56%
Revenues
100m
+19.18%
04,506,3015,777,8657,566,3708,112,61011,610,49410,160,96415,313,17922,014,14026,811,08621,201,48231,557,00046,291,00059,257,00067,449,00072,050,00083,570,00099,597,000
Net income
9m
P
-38,382-2,104,476-907,568-2,051,676-7,894,984-11,662,426-4,419,525-5,388,185-2,771,067-2,928,185-11,377,618-33,316,000-31,471,000-18,483,000-25,557,000-14,449,000-4,938,0008,550,000
CFO
12m
+70.14%
-38,483-1,921,371-396,172-2,661,550-4,098,829-10,119,713-3,906,011-2,580,406-2,111,138-2,936,596-9,804,178-20,908,000-20,439,000-10,600,000-24,163,000-15,098,0007,117,00012,109,000
Earnings
Aug 05, 2025

Profile

ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers, as well as to distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and IMMULINA, a Braun-type lipoproteins, including spirulina extracts and active compounds, which are used to support human immune function. It also offers analytical reference standards and services comprising supply of products to conduct quality control of raw materials and consumer products in dietary supplements, cosmetics, food and beverages, life sciences, and pharmaceutical industries. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation is headquartered in Los Angeles, California.
IPO date
Jun 25, 2007
Employees
113
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122016‑00
Income
Revenues
99,597
19.18%
83,570
15.99%
72,050
6.82%
Cost of revenue
91,871
89,169
90,678
Unusual Expense (Income)
NOPBT
7,726
(5,599)
(18,628)
NOPBT Margin
7.76%
Operating Taxes
305
(2,091)
Tax Rate
3.95%
NOPAT
7,421
(5,599)
(16,537)
Net income
8,550
-273.15%
(4,938)
-65.82%
(14,449)
-43.46%
Dividends
Dividend yield
Proceeds from repurchase of equity
7,747
BB yield
-6.61%
Debt
Debt current
994
1,404
696
Long-term debt
4,308
5,852
7,818
Deferred revenue
2,579
3,311
3,955
Other long-term liabilities
3,955
Net debt
(39,206)
(20,069)
(11,727)
Cash flow
Cash from operating activities
12,109
7,117
(15,098)
CAPEX
(163)
(148)
(334)
Cash from investing activities
(143)
(143)
(334)
Cash from financing activities
5,369
(90)
7,654
FCF
9,562
1,446
(20,836)
Balance
Cash
44,508
27,325
20,241
Long term investments
Excess cash
39,528
23,146
16,638
Stockholders' equity
(181,837)
(190,389)
(185,422)
Invested Capital
233,161
226,837
226,261
ROIC
3.23%
ROCE
15.05%
EV
Common stock shares outstanding
79,724
74,985
69,729
Price
5.31
270.98%
1.43
-14.88%
1.68
-55.08%
Market cap
422,938
294.43%
107,229
-8.46%
117,145
-53.38%
EV
383,732
87,160
105,418
EBITDA
9,210
(3,894)
(16,744)
EV/EBITDA
41.66
Interest
3
Interest/NOPBT